Far East Bio-Tec. Co., Ltd.
TTPEX:688641.10
TWD
-0.05
(-0.12%)
ISIN
TW0006886005
Return %
Stock
S&P 500
1Y
-3.71
14.20
3Y
17.41
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Zhuangqun Que
- Full Time Employees
- 121
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- Room A Taipei TPQ Taiwan 115
- IPO Date
- Apr 27, 2023
- Website
- febico.com.tw
- Similar Companies
- Business
- Far East Bio-Tec Co., Ltd. (Ticker: 6886.TWO) is a Taiwan-based manufacturer specializing in organic microalgae products and dietary supplements. Founded in 1976 and headquartered in Taiwan, the company produces a wide range of health and nutrition products including Organic Spirulina, Organic Chlorella, Spirulina Natural, Chlorella Natural, Chlorella Growth Factor (CGF), DHA algae oil, nattokinase, probiotics, and other microalgae-based superfoods and nutritional supplements. FEBICO supplies these products globally to over 60 countries, leveraging advanced fermentation technology and facilities that ensure high-quality standards compliant with Naturland, EU, and USDA-NOP organic certifications. The company also offers finished products, raw powders, bulk tablets, and private labeling and OEM/ODM services for spirulina and chlorella under its FEBICO brand. In addition, FEBICO manufactures phycobiliproteins such as R-Phycoerythrin, B-Phycoerythrin, and Allophycocyanin, which are used in scientific applications like flow cytometry and immunoassays. Recent major developments include the completion of a merger with AlgaPharma Biotech Corp. in November 2024, enhancing its capabilities in microalgae-based biotechnology, protein purification, biopharmaceutical development, research reagents, and diagnostic biomolecules. In December 2024, FEBICO entered a strategic partnership with Shiny Brands Group Co., Ltd., involving a private placement of shares and a collaborative effort to commercialize the company's new research achievement of microalgae exosomes. This partnership aims to combine FEBICO’s R&D excellence with Shiny Brands’ marketing expertise to expand high-value product offerings in domestic and international skincare and health supplement markets. FEBICO also achieved recognition through the Dun & Bradstreet 12th Top 1000 SME Elite Award in Taiwan in 2025, reflecting its sustained growth and market leadership. FEBICO operates primarily in the biotechnology and nutraceutical segments, targeting global health-conscious consumers and enterprises requiring premium organic microalgae ingredients and supplements. Its nearly five decades of experience and comprehensive product portfolio position it as a leading innovator in the organic microalgae and dietary supplements industry globally. The company maintains a strong presence in Taiwan while actively expanding its market reach internationally through strategic alliances and technological innovation.